Suppr超能文献

基于微环境 pH 调节固体分散体,肠溶性和亲水性聚合物可提高难溶性酸性药物的溶解和吸收。

Enteric and hydrophilic polymers enhance dissolution and absorption of poorly soluble acidic drugs based on micro-environmental pH-modifying solid dispersion.

机构信息

The Department of Veterinary Parasitology, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China; NMPA Key Laboratory for Research and Evaluation of Generic Drugs, Beijing Key Laboratory of Analysis and Evaluation on Chinese Medicine, Beijing Institute for Drug Control, Beijing 102206, China.

The Department of Veterinary Parasitology, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China; Institute of Animal Quarantine, Chinese Academy of Inspection and Quarantine, Beijing 100176, China.

出版信息

Eur J Pharm Sci. 2022 Jan 1;168:106074. doi: 10.1016/j.ejps.2021.106074. Epub 2021 Nov 16.

Abstract

The oral bioavailability of poorly water-soluble active pharmaceutical ingredient (API) is often inadequate for the desired therapeutic effect. Micro-environmental pH-modifying solid dispersion (micro pHm SD) is an effective method for enhancing the dissolution of pH-dependent soluble APIs. However, erratic bioavailability of these drugs was often found when the micro pHm SD of the drugs was orally administrated and passed through the gastrointestinal tract. Because the added alkalizer in micro pHm SD could be neutralized by the acid in the stomach, as a result not enough alkalizer is left to form alkaline micro-environment around the drug in the intestine, leading to poor dissolution and bioavailability of API. Enteric polymers are applicable materials for site-specific drug delivery that are insoluble in gastric tract but soluble in the intestine targeted for drug release. In this study, a poorly water-soluble model drug, toltrazuril (TOL), was prepared as enteric micro pHm SD with enteric, hydrophilic polymers and alkalizer. The surface of enteric micro pHm SD tablets staining and alkalizer protection test in the acid dissolution medium qualitatively and quantitatively confirmed the protective effects of the enteric polymer on the alkalizer. Dissolution studies revealed that the drug release from the enteric micro pHm SDs was improved significantly compared with micro pHm SD with no enteric polymer. The pH-dependent solubility of enteric polymer had effects on the dissolution of APIs from the SDs in neutral medium. Enteric micro pHm SDs with higher proportion of enteric polymer showed higher C and dissolution rate of TOL. The physicochemical characterization and the molecular interaction between drug and matrix were analyzed by electron microscopy (SEM), differential scanning calorimetry (DSC), and fourier transform infrared spectroscopy (FTIR), finding that the formation of hydrogen bonds between TOL and matrix was helpful to promote dissolution of TOL. Ca(OH)-TOL-PVPk30-HPMCAS 8: 8: 18: 6 was determined as the most optimal enteric micro pHm SD, which significantly improved the bioavailability of TOL and its active metabolism (TOLSO, TOLSO) in pharmacokinetic study and could effectively reduce the irritation of the gastrointestinal mucosa caused by the alkalizer Ca(OH) when the SD was orally administrated to rabbits. The present study demonstrates that formulating APIs with poor water solubility as enteric micro pHm SD is an effective method for protecting the alkalizer in SD and improving the dissolution of APIs and the bioavailability following oral administration.

摘要

对于水溶性差的活性药物成分 (API),其口服生物利用度往往不足以为达到预期的治疗效果。微环境 pH 调节固体分散体 (micro pHm SD) 是提高 pH 依赖性可溶性 API 溶解的有效方法。然而,当这些药物的 micro pHm SD 经口给药并通过胃肠道时,其生物利用度往往不稳定。因为 micro pHm SD 中添加的碱化剂会被胃中的酸中和,因此在肠道中没有足够的碱化剂形成药物周围的碱性微环境,导致 API 的溶解和生物利用度差。肠溶性聚合物是适用于局部给药的材料,它们在胃中不溶但在靶向释放药物的肠道中溶解。在这项研究中,将一种水溶性差的模型药物托曲珠利 (TOL) 制备成具有肠溶性、亲水性聚合物和碱化剂的肠溶性 micro pHm SD。肠溶性 micro pHm SD 片剂在酸性溶出介质中的表面染色和碱化剂保护试验定性和定量证实了肠溶性聚合物对碱化剂的保护作用。溶出研究表明,与无微溶性聚合物的 micro pHm SD 相比,药物从肠溶性 micro pHm SD 的释放得到了显著改善。肠溶性聚合物的 pH 依赖性溶解度对中性介质中 SD 中 API 的溶解有影响。具有较高比例肠溶性聚合物的肠溶性 micro pHm SD 显示出更高的 TOL 的 C 和溶解速率。通过电子显微镜 (SEM)、差示扫描量热法 (DSC) 和傅里叶变换红外光谱 (FTIR) 分析了药物与基质之间的物理化学特性和分子相互作用,发现 TOL 与基质之间氢键的形成有助于促进 TOL 的溶解。Ca(OH)-TOL-PVPk30-HPMCAS 8:8:18:6 被确定为最理想的肠溶性 micro pHm SD,它显著提高了 TOL 的生物利用度及其在药代动力学研究中的活性代谢物 (TOLSO、TOLSO),并且可以有效地减少 SD 口服给予兔子时碱化剂 Ca(OH) 引起的胃肠道黏膜刺激。本研究表明,将水溶性差的 API 制成肠溶性 micro pHm SD 是保护 SD 中碱化剂、提高 API 溶解度和口服给药后生物利用度的有效方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验